New pathway cuts red tape and brings predictability to Medicare coverage for Breakthrough Devices.
Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Companies and researchers often fail to disclose negative trial results, resulting in significant gaps in the public record and a publication bias that obscures the true landscape of drug development outcomes—overrepresenting successes and underrepresenting failures. This gap can also create a distorted perception of the safety and efficacy of medical products.
Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, this next‑generation, adjustable‑diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease, according to the company.
The FDA has approved the NEXUS Aortic Arch Stent Graft enabling commercial launch of the NEXUS System in the US.
The InVera Infusion Device is approved for use in the US and EU within its indications.
Allevion Medical Receives FDA Clearance for Vantage™, Introducing a Fully Disposable Approach to Minimally Invasive Spinal Decompression.
The company’s River stent will be available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy.
Companies that embed Market Access early in innovation are the ones best positioned to navigate the changing global landscape.
Nephrodite’s technology improves the lives of dialysis patients. OrthoPreserve’s device addresses challenges faced by those who suffer from chronic knee pain.